Novavax to Participate in H.C. Wainwright Fireside Chat Series
Novavax, a biotechnology company focused on vaccines, will have its Chief Business Officer, John J. Trizzino, participate in the H.C. Wainwright Virtual Fireside Chat on June 25, 2020, at 10:00 a.m. ET. The discussion will center on Novavax's COVID-19 vaccine candidate, NVX-CoV2373. This candidate is part of Novavax's broader mission to develop innovative vaccines, including the NanoFlu™, which recently succeeded in a Phase 3 trial. More insights can be found on Novavax's website.
- None.
- None.
GAITHERSBURG, Md., June 24, 2020 (GLOBE NEWSWIRE) -- Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that John J. Trizzino, Senior Vice President, Chief Business Officer and Chief Financial Officer, will participate in the H.C. Wainwright Virtual Fireside Chat Series on Thursday, June 25. A topic of discussion will be Novavax’ COVID-19 vaccine candidate, NVX-CoV2373.
Fireside chat details are as follows:
| Date: | June 25, 2020 | ||
| Time: | 10:00 a.m. U.S. Eastern Time (ET) | ||
| Webcast: | www.novavax.com, “Investors”/ “Events”, until September 25, 2020 |
About Novavax
Novavax, Inc. (Nasdaq:NVAX) is a late-stage biotechnology company that promotes improved health globally through the discovery, development, and commercialization of innovative vaccines to prevent serious infectious diseases. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2, the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults. Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies. Novavax is a leading innovator of recombinant vaccines; its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles in order to address urgent global health needs.
For more information, visit www.novavax.com and connect with us on Twitter and LinkedIn.
Investors
Silvia Taylor and Erika Trahan
ir@novavax.com
240-268-2022
Media
Brandzone/KOGS Communication
Edna Kaplan
kaplan@kogspr.com
617-974-8659
FAQ
What is the date and time of Novavax's virtual fireside chat?
Who will represent Novavax at the fireside chat?
What will be discussed during the Novavax fireside chat?
Where can I watch the Novavax fireside chat?
What is the significance of NVX-CoV2373 for Novavax?
